Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, Lopez-Casas PP, Jambrina A, Capone C, Vanden Broecke AM, Trevisan M, Van Sanden S, Jürgens A, Herrera-Imbroda B, Castro E. Olmos D, et al. Among authors: trevisan m. Ann Oncol. 2024 May;35(5):458-472. doi: 10.1016/j.annonc.2024.01.011. Epub 2024 Feb 27. Ann Oncol. 2024. PMID: 38417742 Free article.
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.
De Santis M, Breijo SM, Robinson P, Capone C, Pascoe K, Van Sanden S, Hashim M, Trevisan M, Daly C, Reitsma F, van Beekhuizen S, Ruan H, Heeg B, Verzoni E. De Santis M, et al. Among authors: trevisan m. Adv Ther. 2024 Aug;41(8):3039-3058. doi: 10.1007/s12325-024-02918-6. Epub 2024 Jul 3. Adv Ther. 2024. PMID: 38958846 Free PMC article. Review.
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.
Roubaud G, Attard G, Boegemann M, Olmos D, Trevisan M, Antoni L, Pascoe K, Capone C, Van Sanden S, Hashim M, Palmer S, Chi K. Roubaud G, et al. Among authors: trevisan m. Eur J Cancer. 2024 Sep;209:114183. doi: 10.1016/j.ejca.2024.114183. Epub 2024 Jun 17. Eur J Cancer. 2024. PMID: 39111209 Clinical Trial.
Data-Driven Thyroglobulin Cutoffs for Low- and Intermediate-Risk Thyroid Cancer Follow-Up: ITCO Real-World Analysis.
Grani G, D'Elia S, Puxeddu E, Morelli S, Arvat E, Nervo A, Spiazzi G, Rolli N, Zatelli MC, Ambrosio MR, Ceresini G, Marina M, Mele C, Aimaretti G, Santaguida MG, Virili C, Crescenzi A, Palermo A, Giaccherino RR, Meomartino L, Castagna MG, Maino F, Trevisan M, De Leo S, Chiofalo MG, Pezzullo L, Sparano C, Petrone L, Dalmazi GD, Napolitano G, Tumino D, Crocetti U, Bertagna F, Deandrea M, Antonelli A, Mian C, Carbone A, Monti S, Porcelli T, Brigante G, Barbaro D, Alfò M, Ferraro Petrillo U, Filetti S, Durante C. Grani G, et al. Among authors: trevisan m. J Clin Endocrinol Metab. 2024 Aug 16:dgae559. doi: 10.1210/clinem/dgae559. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39150986
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project.
Baldo F, Erkens RGA, Mizuta M, Rogani G, Lucioni F, Bracaglia C, Foell D, Gattorno M, Jelusic M, Anton J, Brogan P, Canna S, Chandrakasan S, Cron RQ, De Benedetti F, Grom A, Heshin-Bekenstein M, Horne A, Khubchandani R, Ozen S, Quartier P, Ravelli A, Shimizu M, Schulert G, Scott C, Sinha R, Ruperto N, Swart JF, Vastert S, Minoia F; PReS MAS/sJIA Working Party and Paediatric Rheumatology International Trial Organization. Baldo F, et al. Rheumatology (Oxford). 2025 Jan 1;64(1):32-44. doi: 10.1093/rheumatology/keae391. Rheumatology (Oxford). 2025. PMID: 39058514 Free PMC article.
877 results